Guernsey's appeal as a jurisdiction for funds is strengthened by the news that leading venture capital and growth equity firm Endeavour Vision has returned to the island for its second dedicated medtech and digital health fund.
Carey Olsen's investment funds team in Guernsey advised Endeavour Vision on the successful launch and final close of Endeavour Medtech Growth II (EMG II) LP, with commitments of US$375 million.
The EMG II LP fund will continue the strategy of its US$250 million predecessor (Endeavour Medtech Growth LP) by investing in high-potential European and US companies delivering transformative healthcare technologies to improve the standard of care for patients and bring efficiencies to healthcare systems. In particular, the fund will focus on growth stage companies that have overcome clinical and regulatory hurdles and are starting to generate commercial traction.
Partner David Crosland let the Carey Olsen team as they advised on all Guernsey aspects of the fund's establishment, regulation, launch and closing.
Mr Crosland said: "The medtech sector continues to evolve rapidly and we're delighted to have assisted Endeavour Vision on the launch of its latest fund which will invest in innovative medtech and digital health solutions to shape the future of healthcare. The successful fundraising demonstrates the high level of confidence in Endeavour as a market-leading investor in this dynamic and vibrant field."
For more information about Guernsey's finance industry please visit www.weareguernsey.com.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
